第一三共

What 第一三共 does

Daiichi Sankyo (China) Holdings Co., Ltd. (第一三共（中国）投资有限公司) is the wholly owned China subsidiary of Japan-based Daiichi Sankyo Co., Ltd. (第一三共株式会社), a Tokyo Stock Exchange-listed company (Ticker: 4568). It officially entered China in 1998 after a market relationship that began in the 1980s, operates with 501–1,000 employees, and serves healthcare professionals, medical institutions, and patients with prescription medicines spanning oncology, cardiovascular, anti-infective, respiratory, and pain-management needs.

The company maintains a China value chain covering research and development, manufacturing, and sales. Its portfolio is organized into oncology, basic treatment, and healthcare categories; oncology includes precision-targeted antibody-drug conjugate medicines, while basic treatment covers cardiovascular, anti-infective, respiratory, and pain-management therapies. Daiichi Sankyo also operates the DS Medical Family Platform (DS 医家平台) for healthcare-professional product information and resources. Its revenue comes from pharmaceutical product sales through direct healthcare-professional and medical-institution channels, with products also sold through pharmacies; product pricing is not publicly disclosed.

Name

第一三共

Legal name

第一三共（中国）投资有限公司

Website

https://daiichisankyo.com.cn

Company type

Private

Founded year

1998

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Daiichi Sankyo (China) develops and sells prescription medicines in China, serving healthcare professionals, medical institutions, and patients across oncology, cardiovascular, anti-infective, respiratory, and pain-management needs, with a core focus on precision-targeted antibody-drug conjugate oncology therapies.

Ownership category

akta.pro rank

Product category

Prescription Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Oncology & Hematology Pharmaceuticals (HLAIAAAC)

akta.pro secondary industries

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE), Specialty Care Pharmaceuticals (HLAIAAAB)

Keywords

• Prescription pharmaceuticals
• Oncology therapeutics
• Cardiovascular medications
• Antibody-drug conjugates
• Specialty medicines

Headquarters

HQ city

Shanghai

HQ country

China

HQ region

Asia

Offices7 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: 第一三共 generates revenue through the sale of innovative pharmaceutical products including oncology drugs, cardiovascular medications, anti-infectives, respiratory treatments, and pain management solutions. Products are distributed through healthcare professional channels and medical institutions in China.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Daiichi Sankyo China develops, manufactures, and sells innovative prescription pharmaceuticals in Mainland China across five therapeutic areas: oncology, cardiovascular, anti-infection, respiratory, and pain management. The company maintains a full in-country value chain from R&D to manufacturing (Shanghai facility) to a direct sales force reaching medical institutions and licensed healthcare professionals, with an emphasis on precision-targeted ADC (antibody-drug conjugate) oncology medicines sourced from its Japanese parent.

Product overview

第一三共 is a global pharmaceutical company with over 120 years of history that offers a portfolio of prescription medications across three main therapeutic areas: Oncology (tumor treatment including ADC-based precision medicines), Basic Treatment (cardiovascular, anti-infection, respiratory, and pain management), and Healthcare products. The company operates through its China subsidiary and provides products in key treatment areas including oncology, cardiovascular, anti-infection, respiratory, and analgesia. A digital platform called DS医家平台 serves healthcare professionals. The company focuses on antibody drug conjugate (ADC) technology for cancer treatment and maintains a full value chain from R&D to manufacturing to sales in China.

Differentiator

Problem solved

Functional benefit

Products and services

• Oncology therapeutics (肿瘤领域) Portfolio of prescription cancer medicines, including precision-targeted Antibody-Drug Conjugate (ADC) drugs, for Chinese oncology patients treated by hospital-based prescribers.
• Basic Treatment therapeutics (基础治疗) Portfolio of prescription medicines covering cardiovascular, anti-infection, respiratory, and pain management indications for Chinese patients, developed using the parent group's innovative drug-discovery and delivery methods.
• Healthcare and wellness products (医药保健) Healthcare and wellness product line offering health management solutions to Chinese consumers within the Daiichi Sankyo China portfolio.

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Scale indicators3 records

Recent moves4 records

Expansion highlights3 records

Direct peers

• Novartis (China): Innovative pharma major with China operations spanning oncology, cardiovascular, and specialty care. Comparable as a branded-innovator peer competing for the same NRDL slots and HCP mindshare.
• Sanofi (China): Multinational pharma with diversified China portfolio across specialty care, cardiovascular, and anti-infectives. Comparable breadth of therapeutic areas and hospital-channel commercialization model.
• Takeda (China): Japanese pharma peer also operating through a China subsidiary structure with specialty/oncology and rare-disease focus. Comparable as a fellow Japan-headquartered multinational innovator operating in China via a similar subsidiary footprint.
• Roche (China): Oncology and specialty-care leader with a major China presence across innovative biologics and diagnostics. Comparable therapeutic mix (oncology dominance with cardiovascular/anti-infective adjacencies) and direct hospital sales model.
• AstraZeneca (China): Global pharma major with a deeply established China commercial footprint spanning oncology (including ADC collaboration with Daiichi Sankyo on Enhertu), cardiovascular, and respiratory. Highly comparable as a multinational innovator-pharma subsidiary competing in the same HCP and hospital channels.
• Pfizer (China): Diversified multinational pharma with oncology, cardiovascular, anti-infective, and pain-management franchises in China. Comparable portfolio breadth, scale of China field sales force, and exposure to NRDL dynamics.
• Bristol-Myers Squibb (China): Global oncology and cardiovascular-focused pharma with established China presence. Comparable given its heavy oncology/immuno-oncology mix and direct hospital sales motion in China.
• Eli Lilly (China): US-headquartered innovator pharma with growing China operations across oncology (Verzenio) and diabetes/cardiovascular. Comparable as a multinational branded-pharma competitor in the same hospital and HCP channels.
• Merck & Co. (MSD China): Global oncology powerhouse (Keytruda) with substantial China presence and hospital-channel oncology sales. Comparable given its oncology-led innovative pharma model and NRDL exposure.
• Bayer (China): Multinational pharma with China operations spanning cardiovascular, oncology, and specialty care. Comparable diversified innovative-pharma portfolio and direct-to-hospital go-to-market motion.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/%E7%AC%AC%E4%B8%80%E4%B8%89%E5%85%B1

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 第一三共